Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | cytoplasmic intermediate filament protein | 0.0017 | 0.2574 | 0.2574 |
Loa Loa (eye worm) | hypothetical protein | 0.0015 | 0.1432 | 0.1432 |
Loa Loa (eye worm) | hypothetical protein | 0.0016 | 0.1725 | 0.1725 |
Echinococcus multilocularis | lamin | 0.0033 | 1 | 1 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0017 | 0.2574 | 0.2574 |
Echinococcus multilocularis | cytoplasmic intermediate filament protein | 0.0016 | 0.1725 | 0.1725 |
Onchocerca volvulus | 0.0033 | 1 | 1 | |
Echinococcus granulosus | lamin dm0 | 0.0033 | 1 | 1 |
Echinococcus multilocularis | musashi | 0.0033 | 1 | 1 |
Onchocerca volvulus | 0.0033 | 1 | 1 | |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 1 | 1 |
Echinococcus granulosus | cytoplasmic intermediate filament protein | 0.0016 | 0.1725 | 0.1725 |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.9707 | 0.9707 |
Schistosoma mansoni | intermediate filament proteins | 0.0033 | 1 | 1 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 1 | 1 |
Schistosoma mansoni | lamin | 0.0033 | 1 | 1 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 1 | 1 |
Echinococcus granulosus | lamin | 0.0033 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0015 | 0.1432 | 0.1432 |
Schistosoma mansoni | lamin | 0.0033 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 10 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 12.5893 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Potency (functional) | = 112.2018 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.